Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7026054 | 1.00 | CA1 (0.47) | CA1CA2TSHRCA12CA7 | |
| SCHEMBL28203667 | 0.87 | TSHR (0.55) | CA1CA2TSHRALDH1A1CASP1 | |
| SCHEMBL7027323 | 0.83 | ALDH1A1 (0.47) | CA1CA2TSHRCA12CA7 | |
| SCHEMBL7025130 | 0.83 | CA1 (0.47) | CA1CA2TSHRCA12CA7 | |
| SCHEMBL7025132 | 0.83 | CA1 (0.47) | CA1CA2TSHRCA12CA7 | |
| SCHEMBL29655541 | 0.82 | CA12 (0.53) | CA1CA2TSHRCA12CA7 | |
| SCHEMBL7029347 | 0.80 | CA12 (0.44) | CA1CA2TSHRCA12CA7 | |
| SCHEMBL7030578 | 0.80 | MRGPRX4 (0.47) | CA1CA2TSHRCA12CA7 | |
| SCHEMBL7028623 | 0.80 | NPC1 (0.47) | CA1CA2TSHRCA12CA7 | |
| SCHEMBL7024833 | 0.80 | CA12 (0.44) | CA1CA2TSHRCA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030088113-A1 | Process for preparing resorcinol derivatives | BRADLEY STUART EDWARD (GB) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030088113-A1 | Process for preparing resorcinol derivatives | CYP4B1, CYP4A11, POR | CA1 4823/4885CA2 4676/4885TSHR 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.